Plain-English translation of NCT06729346 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at a special imaging technique called narrow-band imaging that doctors use during bladder cancer surgery. The goal is to find out whether this imaging can detect cancer cells that are hidden or invisible when using standard white light imaging. This matters because some bladder cancers are very small or flat and easy to miss, which could affect how well treatment works.
During bladder cancer surgery, doctors currently rely on what they can see with regular white light. However, some cancer cells—including a dangerous type called carcinoma in situ—may not be visible with standard imaging. This study exists to determine whether this special imaging technique can help doctors find and treat cancers they might otherwise overlook.
You likely qualify if…
You likely don't qualify if…
If you qualify for this study, you would have imaging scans performed during your scheduled bladder cancer surgery. During your surgery, doctors would use both standard white light imaging and the special narrow-band imaging technique to examine your bladder. The study team would then compare what each imaging method can see to understand whether the special technique finds cancers that standard imaging misses.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Pakistan
Enrollment target
~100 participants
Started
December 2024
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
azmat ullah, consultant urologist
armed forces institute of urology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.